Hikma Pharmaceuticals PLC (OTCPK:HKMPF) Q4 2024 Results Conference Call February 26, 2025 2:00 AM ET
Company Participants
Riad Mishlawi – Chief Executive Officer
Khalid Nabilsi – Chief Financial Officer
Riad Mishlawi
Thank you for joining our 2024 full year results presentation. I am Riad Mishlawi, CEO of Hikma, and I am joined here with Khalid Nabilsi, our CFO. I will kick off by providing a quick summary of our results and an update on our strategic progress. I will then hand over to Khalid to take us through the financials in more detail.
I have been in the CEO role now for just over a year and I am pleased with the progress we’ve made to date we delivered an excellent financial performance, ahead of our initial expectations, and I’m very confident that we have the right strategy in place to deliver growth for many years to come. We achieved Group core revenue growth of 10% for 2024, ahead of our upgraded guidance of 6% to 8% for the year, demonstrating the strength of our three business segments, each unique, but together providing differentiation, diversification and exciting potential. We also delivered core operating profit of $719 million, in line with our guidance. This is a great result, particularly in a year where we had a profit headwind in our Generics business.
Importantly, we’ve continued to strengthen our platform for future growth, supported by our ability to consistently deliver high levels of returns on invested capital. Last year, I set out our refreshed strategy, which focuses on three key pillars for growth, which are: strive for excellence, diversify and differentiate, and people and responsibility. 2024 has been a year of great strategic progress and I’m pleased with how we are putting our plans into action.
Going through this in turn, starting with
#Hikma #Pharmaceuticals #PLC #HKMPF #Earnings #Call #PreRecorded #Transcript